제품 정보로 건너뛰기
1 의 1

ELK Biotechnology

SKU(재고 관리 코드):EPT202

Recombinant Human TNF alpha (N-6His)

Recombinant Human TNF alpha (N-6His)

가격·납기 및 기술자료를 확인해 드립니다.

제품 규격과 수량을 선택한 후 견적을 요청해 주세요. 대체품 검토와 SDS·COA·데이터시트 요청도 함께 접수할 수 있습니다.

이 제품 견적 요청

대표번호 070-8028-3500 · info@rndmate.com

MULTI-BRAND QUOTE
여러 제품을 함께 찾고 계신가요?
제조사가 달라도 괜찮습니다. 필요한 연구시약을 한 번에 견적받아보세요.
통합 견적 요청
Size
Description: Recombinant Human Tumor Necrosis Factor Alpha is produced by our E.coli expression system and the target gene encoding Gly57-Leu233 is expressed with a 6His tag at the N-terminus.
Accession: P01375
Molecular weight: 21.8 KDa
Apparent molecular weight: 18 KDa, reducing conditions
Other names: Tumor Necrosis Factor; Cachectin; TNF-Alpha; Tumor Necrosis Factor Ligand Superfamily Member 2; TNF-a; TNF; TNFA; TNFSF2
Storage condition: Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Purity: Greater than 95% as determined by reducing SDS-PAGE.
Endotoxin: Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Redissolve: Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. 
Storage: Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Delivery condition: The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Background: Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. Based on these results, many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.
전체 세부 정보 보기